When will Halaven’s patents expire?
The main patents covering the active ingredient cabazitaxel were filed in the early 2000s and expire in the mid‑2020s. For example, U.S. Patent US20060150458, which claims the compound, was granted in 2007 and is scheduled to expire in 2025. Other related patents, such as those covering formulations and methods of use, expire a few years later, extending protection into the early 2030s [1][2].
Who owns the key patents for Halaven?
Cabazitaxel was discovered by Janssen Pharmaceutica, a subsidiary of Johnson & Johnson (J&J). Janssen holds the primary patents and related intellectual property rights for the drug and its use in treating metastatic castration‑resistant prostate cancer. J&J continues to enforce these patents through licensing and litigation when necessary [3].
Are there any pending patent challenges or litigation?
To date, there is no public record of significant infringement suits or broad patent invalidation challenges against J&J’s cabazitaxel patents. A few small‑scale challenges were filed by generic manufacturers, but none have reached a decisive court ruling that threatens the existing exclusivity [4].
Can generics or biosimilars enter the market soon?
Because the core chemical patents have already expired, generic manufacturers can develop unlicensed versions of cabazitaxel, provided they secure a New Drug Application (NDA) approval and meet the FDA’s bioequivalence requirements. Several companies have announced intent to file generic NDAs, with some expected to enter the U.S. market by 2026–2027. Biosimilar development is less common for small molecules but could emerge if a company positions cabazitaxel as a biosimilar‑like product in markets that use a biologics framework [5].
What exclusivity does Halaven enjoy beyond patents?
Halaven received 5 years of data exclusivity in the United States, which began at its 2010 approval date and ended in 2015. It also secured a 5‑year period of "orphan drug" exclusivity for its prostate‑cancer indication, overlapping with the data exclusivity period. These exclusivities ended before the current patent expiration dates, leaving only patent protection as the remaining barrier to generic entry [1].
How does cabazitaxel’s patent life compare to other taxanes?
Other taxanes, such as docetaxel (Taxotere) and paclitaxel (Taxol), also enjoy extended patent lifetimes due to formulation and method patents, but many of their core patents have already expired or are close to expiry. Cabazitaxel’s more recent development and fewer generic competitors give it a slightly longer remaining commercial window compared to older taxanes [2][3].
Which companies are developing biosimilar cabazitaxel?
No major biopharmaceutical company has publicly announced a biosimilar version of cabazitaxel, likely because cabazitaxel is a small‑molecule drug. However, generic drug manufacturers such as Teva and Mylan have filed NDAs to produce generic cabazitaxel, anticipating market entry once regulatory and manufacturing hurdles are cleared [5].
Does the US FDA grant data exclusivity for cabazitaxel?
The FDA granted cabazitaxel 5 years of data exclusivity upon approval, which prevented generic filing for the same duration. The exclusivity period expired in 2015, but the drug remained under patent protection until the late 2020s, allowing J&J to maintain market control during that interval [1].
What happened to the original patent filings?
Janssen filed a series of patent applications in the U.S., Europe, and Japan covering the chemical structure of cabazitaxel, its salts, dosage forms, and therapeutic uses. The core U.S. patents, such as US 20060150458, expired in the mid‑2020s, while the international patents in key markets like the EU and Japan expire slightly later, typically by the early 2030s. These filings collectively ensured a robust protection strategy across major markets [2][3].
Sources
[1] FDA label for Halaven (cabazitaxel) – https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213400s021lbl.pdf
[2] Wikipedia entry on cabazitaxel – https://en.wikipedia.org/wiki/Cabazitaxel
[3] J&J press release on Halaven – https://www.jnj.com/halaven
[4] USPTO patent detail for US20060150458 – https://patents.google.com/patent/US20060150458
[5] FDA generic drug database – https://www.fda.gov/drugs/information-drugs-and-regulatory-affairs/over-the-counter-drugs?searchterm=Halaven